Abstract
SMARCA4-deficient sarcoma was first reported in the chest and recently in the uterus, but not in the stomach. Here, we present a patient diagnosed with SMARCA4-deficient sarcoma of the stomach, using histochemistry. An emergency operation was performed due to perforation of the tumor. However, one month after the operation, two nodes recurred, and six cycles of combination chemotherapy consisting of adriamycin and ifosfamide were administered. The combination chemotherapy showed a remarkable effect, and complete remission was achieved. The patient was alive without recurrence after 48-month follow-up. SMARCA4-deficient sarcoma is an exceedingly rare tumor with an extremely poor therapeutic response to anticancer drugs. Herein, we present the first case of SMARCA4-deficient sarcoma of the stomach, where a complete response to chemotherapy was achieved.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- SOX2:
-
SRY (sex determining region Y)-box 2
- SALL4:
-
Sal-like protein 4
- CCNB3:
-
Cyclin B3
- TLE-1:
-
Transducin-like enhancer protein 1
- WT1:
-
Wilms tumor 1
- HMB45:
-
Human melanoma black
- NUT:
-
Nuclear protein in testis
References
Yoshida A, Kobayashi E, Kubo T, et al. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. Modern Pathol. 2017;30:797–809.
Kuwamoto S, Matsushita M, Takeda K, et al. SMARCA4-deficient thoracic sarcoma: report of a case and insights into how to reach the diagnosis using limited samples and resources. Hum Pathol. 2017;70:92–7.
Crombe A, Alberti N, Villard N, et al. Imaging features of SMARCA4-deficient thoracic sarcomas: a multi-centric study of 21 patients. Eur Radiol. 2019;29:4730–41.
Perret R, Chalabreysse L, Watson S, et al. SMARCA4-deficient thoracic sarcomas: clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnoses. Am J Surg Pathol. 2019;43:455–65.
Le Loarer F, Watson S, Pierron G, et al. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet. 2015;47:1200–5.
Tang L, Nogales E, Ciferri C, et al. Structure and function of SWI/SNF chromatin remodeling complexes and mechanistic implications for transcription. Progr Biophys Mol Biol. 2010;102:122–8.
Wu JI, Lessard J, Crabtree GR, et al. Understanding the words of chromatin regulation. Cell. 2009;136:200–6.
Kadoch C, Hargreaves DC, Hodges C, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet. 2013;45:592–601.
Shain AH, Pollack JR, et al. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS ONE. 2013;8:e55119.
Kolin DL, Dong F, Baltay M, et al. SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma. Modern Pathol. 2018;31:1442–56.
Lin DI, Allen JM, Hecht JL, et al. SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association. Modern Pathol. 2019;32:1675–87.
Rosenberg AE. WHO classification of soft tissue and bone, fourth edition: summary and commentary. Curr Opin Oncol. 2013;25:571–3.
Sauter JL, Graham RP, Larsen BT, et al. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior. Modern Pathol. 2017;30:1422–32.
Alimova I, Birks K, Harris S, et al. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. Neuro Oncol. 2013;15:149–60.
Chan-Penebre E, Armstrong K, Drew A, et al. Selective killing of SMARCA2- and SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type cells by inhibition of EZH2. In vitro and in vivo preclinical models. Mol Cancer Ther. 2017;16:850–60.
Iijima Y, Sakakibara R, Ishizuka M, et al. Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report. Immunotherapy. 2020;12:563–9.
Agaimy A, Daum O, Märkl B, et al. SWI/SNF complex-deficient undifferentiated/rhabdoid carcinomas of the gastrointestinal tract: a series of 13 cases highlighting mutually exclusive loss of SMARCA4 and SMARCA2 and frequent co-inactivation of SMARCB1 and SMARCA2. Am J Surg Pathol. 2016;40:544–53.
Rekhtman N, Montecalvo J, Chang JC, et al. SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol. 2020;15:231–47.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
TI received scholarship fund from Nippon Kayaku Co. Ltd., and Shionogi Pharma Co. Ltd.. YI received scholarship fund from Shionogi Pharma Co. Ltd.. The other authors declare no competing interests.
Human rights statement and informed consent
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study, or the equivalent, was obtained from our patient.
Informed Consent
Informed consent was obtained from all patients for being included in the study
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ota, T., Ishikawa, T., Yasuda, R. et al. The first case of SMARCA4-deficient sarcoma of stomach. Clin J Gastroenterol 15, 531–536 (2022). https://doi.org/10.1007/s12328-022-01606-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12328-022-01606-8